862073-77-6|Herkinorin|Herkinorin, mu opioid agonist|-范德生物科技公司

Herkinorin

NMR下载 COA and HPLC MSDS下载
names：
Herkinorin, mu opioid agonist
CAS号：
862073-77-6
MDL Number：
MF(分子式)： C28H30O8 MW(分子量)： 494.54
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

Herkinorin 是一种有效且选择性的 μ阿片受体激动剂，Ki 为 45 nM。Herkinorin 被广泛用于疼痛研究

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	Herkinorin(862073-77-6)；μ阿片受体激动剂；非内化μ阿片受体激动剂；Non-internalising μ opioid agonist
英文别名	Herkinorin, mu opioid agonist(862073-77-6)；BF3DNCA methyl ester；Herkinorin.
CAS号	862073-77-6
Inchi	InChI=1S/C28H30O8/c1-27-11-9-18-26(32)36-21(17-10-12-34-15-17)14-28(18,2)23(27)22(29)20(13-19(27)25(31)33-3)35-24(30)16-7-5-4-6-8-16/h4-8,10,12,15,18-21,23H,9,11,13-14H2,1-3H3
InchiKey	PYDQMXRFUVDCHC-UHFFFAOYSA-N
分子式 Formula	C28H30O8
分子量 Molecular Weight	494.54
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	Herkinorin(CAS:862073-77-6):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	Herkinorin is an opioid analgesic that is an analogue of the natural product Salvinorin A. Unlike Salvinorin A which is a selective κ-opioid agonist with no significant μ-opioid receptor affinity, herkinorin is a μ-opioid agonist with more than 100x higher μ-opioid affinity and 50x lower κ-opioid affinity compared to Salvinorin A. Herkinorin is a semi-synthetic compound, made from Salvinorin B, which is most conveniently made from Salvinorin A by deacetylation, as while both Salvinorin A and Salvinorin B are found in the plant Salvia divinorum, Salvinorin A is present in larger quantities.
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Butelman ER, Rus S, Simpson DS, Wolf A, Prisinzano TE, Kreek MJ. The effects of herkinorin, the first mu-selective ligand from a salvinorin A-derived scaffold, in a neuroendocrine biomarker assay in nonhuman primates. J Pharmacol Exp Ther. 2008 Oct;327(1):154-60. doi: 10.1124/jpet.108.140079. Epub 2008 Jul [1] PubMed PMID: 18593955; PubMed Central PMCID: PMC2614932.

[2]Ji F, Wang Z, Ma N, Riley J, Armstead WM, Liu R. Herkinorin dilates cerebral vessels via kappa opioid receptor and cyclic adenosine monophosphate (cAMP) in a piglet model. Brain Res. 2013 Jan 15;1490:95-100. doi: 10.1016/j.brainres.2012.10.024. Epub 2012 Oct 24. PubMed PMID: 23103502; PubMed Central PMCID: PMC3529796.

[3] Lamb K, Tidgewell K, Simpson DS, Bohn LM, Prisinzano TE. Antinociceptive effects of herkinorin, a MOP receptor agonist derived from salvinorin A in the formalin test in rats: new concepts in mu opioid receptor pharmacology: from a symposium on new concepts in mu-opioid pharmacology. Drug Alcohol Depend. 2012 Mar 1;121(3):181-8. doi: 10.1016/j.drugalcdep.2011.10.026. Epub 2011 Nov 26. PubMed PMID: 22119134; PubMed Central PMCID: PMC3288203.

[4] Xu H, Partilla JS, Wang X, Rutherford JM, Tidgewell K, Prisinzano TE, Bohn LM, Rothman RB. A comparison of noninternalizing (herkinorin) and internalizing (DAMGO) mu-opioid agonists on cellular markers related to opioid tolerance and dependence. Synapse. 2007 Mar;61(3):166-75. PubMed PMID: 17152090.

[5] Rowan MP, Bierbower SM, Eskander MA, Szteyn K, Por ED, Gomez R, Veldhuis N, Bunnett NW, Jeske NA. Activation of mu opioid receptors sensitizes transient receptor potential vanilloid type 1 (TRPV1) via β-arrestin-2-mediated cross-talk. PLoS One. 2014 Apr 2;9(4):e93688. doi: 10.1371/journal.pone.0093688. eCollection 2014. PubMed PMID: 24695785; PubMed Central PMCID: PMC3973553.

6: Tidgewell K, Groer CE, Harding WW, Lozama A, Schmidt M, Marquam A, Hiemstra J, Partilla JS, Dersch CM, Rothman RB, Bohn LM, Prisinzano TE. Herkinorin analogues with differential beta-arrestin-2 interactions. J Med Chem. 2008 Apr 24;51(8):2421-31. doi: 10.1021/jm701162g. Epub 2008 Apr 2. PubMed PMID: 18380425; PubMed Central PMCID: PMC2494883.7: Bartuzi D, Kaczor AA, Matosiuk D. Activation and Allosteric Modulation of Human μ Opioid Receptor in Molecular Dynamics. J Chem Inf Model. 2015 Nov 23;55(11):2421-34. doi: 10.1021/acs.jcim.5b00280. Epub 2015 Nov 11. PubMed PMID: 26517559.8: Prisinzano TE. Neoclerodanes as atypical opioid receptor ligands. J Med Chem. 2013 May 9;56(9):3435-43. doi: 10.1021/jm400388u. Epub 2013 Apr 18. Review. PubMed PMID: 23548164; PubMed Central PMCID: PMC3671615.9: Sally EJ, Xu H, Dersch CM, Hsin LW, Chang LT, Prisinzano TE, Simpson DS, Giuvelis D, Rice KC, Jacobson AE, Cheng K, Bilsky EJ, Rothman RB. Identification of a novel "almost neutral" micro-opioid receptor antagonist in CHO cells expressing the cloned human mu-opioid receptor. Synapse. 2010 Apr;64(4):280-8. doi: 10.1002/syn.20723. PubMed PMID: 19953652; PubMed Central PMCID: PMC2821452.10: Marmolejo-Valencia AF, Martínez-Mayorga K. Allosteric modulation model of the mu opioid receptor by herkinorin, a potent not alkaloidal agonist. J Comput Aided Mol Des. 2017 May;31(5):467-482. doi: 10.1007/s10822-017-0016-7. Epub 2017 Mar 31. PubMed PMID: 28364251.1

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开